Cangrelor is an intravenous P2Y₁₂ platelet inhibitor used primarily during percutaneous coronary intervention (PCI) to prevent blood clots. It is ideal for patients not pretreated with oral P2Y₁₂ inhibitors (e.g., clopidogrel, ticagrelor, or prasugrel).
How Cangrelor Works: Rapid Reversible Antiplatelet Action
Drug Class: Reversible IV P2Y₁₂ receptor antagonist
Mechanism: Blocks ADP-induced platelet activation → prevents thrombus formation
Onset of Action: ~2 minutes
Half-life: 3–6 minutes
Recovery Time: Platelet function returns to normal within 1 hour after discontinuation
Its fast onset and short duration make this medication a flexible and reliable option in emergency and high-risk PCI settings.
FDA-Approved Indications
- Adjunct to PCI
For patients not previously treated with oral P2Y₁₂ inhibitors
Especially useful in urgent or emergency PCI cases - Bridging Therapy
Temporary antiplatelet management in patients awaiting surgery (e.g., CABG) where oral antiplatelets must be paused
Cangrelor Dosage and Administration Guidelines
During PCI:
- IV Bolus: 30 µg/kg immediately before PCI
- Infusion: 4 µg/kg/min for at least 2 hours or the PCI duration
For Bridging Use:
- Continuous infusion at 0.75 µg/kg/min until oral agents can be resumed
Benefits of Cangrelor Over Oral Antiplatelets
- Instant platelet inhibition — no GI absorption needed
- Reversible within 1 hour — safer in high bleeding risk scenarios
- Allows precise control in critical care and surgical bridging
Potential Side Effects
Common:
- Minor bleeding
- Mild dyspnea
Serious (rare):
- Severe bleeding (GI or intracranial)
- Hypersensitivity reactions
Always monitor for signs of active bleeding, especially in high-risk patients.
Contraindications
Avoid using this medication if the patient has:
- Ongoing active bleeding
- Severe hepatic dysfunction
- Hypersensitivity to cangrelor
- Concurrent use with other IV antiplatelets
Drug Interactions and Transitioning to Oral Therapy
Transition Tip: After stopping cangrelor, give:
- Clopidogrel 600 mg
- Ticagrelor 180 mg
- Prasugrel 60 mg
Avoid overlapping with other anticoagulants (e.g., warfarin, heparin, NSAIDs) unless under clinical supervision.
Monitoring and Perioperative Considerations
- No INR or platelet function testing required
- Ideal for NPO patients or urgent PCI
- Pause the infusion 1–3 hours before surgery to allow complete platelet recovery.
Clinical Evidence: CHAMPION Trials
Clinical trials validated the safety and efficacy of this medicine, showing:
- Reduced risk of major cardiac events during PCI
- Comparable bleeding risk to clopidogrel when managed correctly
Cost vs. Clinical Value
Approximate cost: $1,000 per PCI
Value: Invaluable in high-risk settings, emergency PCI, or when oral therapy isn’t an option
Why Choose Amber Lifesciences for Cangrelor?
Amber Lifesciences Pvt. Ltd. is a trusted pharmaceutical manufacturer and global supplier, delivering high-quality, reliable medications like cangrelor online in Latin American countries such as Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, and the Dominican Republic. Our commitment to strict quality control, adherence to international regulatory standards, and state-of-the-art manufacturing facilities ensures that every batch meets the highest safety and efficacy criteria. Thanks to streamlined global logistics and competitive pricing, Amber Lifesciences delivers smooth supply solutions, earning the trust of healthcare providers and distributors around the world.
Conclusion – Why Choose Cangrelor?
This medicine is the fastest-acting IV antiplatelet agent, ideal for patients undergoing PCI who haven’t taken oral P2Y₁₂ inhibitors. With rapid onset, quick reversal, and proven efficacy, it is a game-changer in acute cardiovascular care. For managing high-risk PCI or surgical bridging cases, it offers safety, speed, and reliability when every second counts.
